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Abstract
Purpose: Two stent types (a new Wallstent and a Z-
stent) were investigated in 30 patients with recurrent
malignant superior vena caval syndrome (SVCS).
Methods: Eligibility requirements were that the patient
had recurrent symptoms after appropriate radiation
therapy, chemotherapy, or both; ¢75% of the vessel
was occluded; and there was collateral flow. Because
of the limited availability of stents, it was not possible
to perform a prospectively randomized study.
Results: In the Z-stent group (17 patients), occlusion of
the stent due to acute thrombosis occurred within 12 hr
in 4 patients (24%), but in the other 13 patients (76%)
symptoms disappeared completely. After 2 weeks the
cavogram in these patients showed no signs of throm-
bosis, and 12 (71%) of the patients remained symptom-
free. There was partial occlusion in 5 patients (29%),
without relevant clinical symptoms. Of the 13 patients
who received Wallstents, only 1 had an acute imme-
diate thrombosis (8%). Symptoms disappeared com-
pletely in the other 12 patients and no signs of
thrombosis were seen. However, after 2 weeks com-
plete stent occlusion with SVCS was found in 3 patients
(23%) and partial occlusion with minor clinical symp-
toms in 6 (46%). Only 3 patients (23%) had complete
relief of their SVCS. The difference between the rates
of occlusion of the two stents after 2 weeks was highly
significant (p  0.008).
Conclusions: The overall clinical success rate for long-
term patency was 100% for the Z-stents and 69% for
the new Wallstent. These results suggest that when
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used for this purpose, the new Wallstent is more throm-
bogenic at 2 weeks than the Z-stent.
Key words: Superior vena caval syndrome—Wallstent
vs. Z-stent—Palliative treatment
Superior vena caval syndrome (SVCS) secondary to
malignant disease is traditionally treated by radiation
therapy, chemotherapy, or both. Initial success rates
have been reported to exceed 90%. Recurrence of
SVCS, however, develops in 10%–20% of patients [1,
2]. It may be caused by tumor recurrence, postradiation
fibrosis, or superimposed thrombosis. Patients treated
with radiation therapy are usually given a maximum-
tolerance dose, so treatment of recurrence is difficult or
impossible. Intraluminal stenting can provide sufficient
force to reopen the vessel lumen and prevent tumor and
thrombotic occlusion.
Since 1986 more than 100 palliative SVCS stent
procedures have been reported in the literature [2–8].
In our initial series of 22 patients [9] with malignant
caval obstruction, palliative stenting was performed
mainly with Z-stents. The complication rate directly
related to the superior vena cava (SVC) was 18%. Stent
occlusion due to thrombosis, tumor encasement, or
both, was the major complication in this group of pa-
tients. A new Wallstent—adapted to the dimensions of
the SVC—might prohibit such occlusion by its closer
wire structure, which prevents tumor ingrowth through
the struts.
The purpose of this study was to compare the re-
sults of these two stents in SVCS patients. Because of
the limited availability of the new Wallstent, it was not
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Fig. 1. A New, longer Wallstent partially released from the delivery
device (diameter 11.5 Fr, length 112 cm, guidewire 0.38 inch). B
Double Gianturco Z-stent partially released from the delivery device
(diameter 11.0 Fr, length 60 cm, guidewire 0.38 inch). Note the un-
folded second part of the double Z-stent.
Fig. 2. A Unfolded longer Wallstent (diameter 20 mm, length 70
mm). B Unfolded Gianturco double Z-stent (diameter 20 mm, length
50 mm). Note that the magnification factor of the two stents is not
the same.
Table 1. Patient characteristics
Characteristic Wallstent Z-stent
No. of patients 13 17
Sex (M/F) 10/3 11/6
Age (years)a 61 (40–74) 60 (45–74)
Tumor type
Lung 9 11
Other 4 6
Previous radiotherapy
No. of patients 11 11
Dose (Gy)a 40 (20–66) 45 (20–60)
Previous chemotherapy 4 8
a Values are the median (range)
possible to conduct a randomized study. A series of 30
patients who had recurrent malignant SVC obstruction
after appropriate radiotherapy, chemotherapy, or both
and in whom palliative stenting was performed with
either the new Wallstent or a Z-stent are reported.
Methods
Patients were accepted for the stent procedure if there was clinical
evidence of recurrent SVCS proved by cavography. All patients had
recurrent symptoms after appropriate external beam radiation ther-
apy, chemotherapy, or both but were not amenable to further therapy.
Patients were required to have a ¢75% vessel occlusion (diameter)
and collateral flow. The following contraindications for the stent pro-
cedure were applied: (1) chronic complete vessel occlusion proved
by computed tomography (CT) or angiography; (2) severe coagulo-
pathy; (3) congestive or ischemic heart disease requiring medication;
(4) impossibility of passing or dilating a high-grade or complete SVC
obstruction.
For the initial diagnostic cavography an 18-gauge Venflon sheath
was placed in the cubital veins of both arms, and 80 ml of iopromide
(300 mg I/ml) injected at a flow rate of 20 ml/sec simultaneously on
the two sides (40 ml each side). If necessary an ultrasound-guided
procedure was performed to place the Venflon sheath in the vessel.
A digital subtraction series of the thorax aperture and mediastinum
was obtained during injection (Digitron 3, Siemens, Erlangen, Ger-
many) using three images per second.
During the diagnostic procedure the optimal approach for passing
and stenting the SVC was explored. Full-dose heparin (25,000 U/
day) was instituted before the stent procedure and continued for a
maximum of 2 weeks after stenting with prolongation of the partial
thromboplastin time (PTT) 2.5-fold, starting 1 day prior to stent
placement. Thereafter, patients received lifetime coumarin antico-
agulant therapy. The stent procedure was performed via the femoral
approach, and immediately before placing the stent a transcatheter
injection of streptokinase 50,000 U was administered locally. After
the procedure streptokinase 10,000 U/hr was administered through
the catheter for 12 hr. Stent procedures were undertaken with contin-
uous electrocardiographic monitoring in all patients. Follow-up cav-
ography was performed in all patients before they were discharged
from the hospital 2 weeks after the operation. This was performed in
the same manner as the initial diagnostic cavography.
The stent introducer diameter varied from 10 Fr for Z-stents to
12 Fr for the Wallstents; balloon dilatation up to 20 mm was per-
formed only before stent placement. In all patients stents were placed
with a guidewire passing the stenosis. The appropriate stent length
was determined during the procedure according to the results of the
diagnostic radiologic series or the balloon dilatation during the in-
terventional session. A follow-up cavogram was performed 2 weeks
after stent placement and a longer follow-up was achieved clinically.
Because the new Wallstent was custom-made and not always
available, the study design was not randomized. Whenever both
stents were available, patients were allocated statistically to either the
Wallstent or the Z-stent group before diagnostic cavography was per-
formed. This assignment appeared to be random, as tested with the
one sample runs test (p  0.05). All patients gave informed consent.
The new Wallstent that was used has the advantage of undergoing
less shortening, compared with former stent designs, after release
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Fig. 3. A Cavography. Subtotal stenosis is seen at
the entry of the superior vena cava (SVC) (ar-
row). Collateral flow is seen at the thorax aper-
ture and retrograde flow in the azygos vein (v). B
Cavography 1 week after stent placement of one
double and one single Z-stent. Unimpaired flow
through the SVC to the right atrium is demon-
strated without collateral flow or retrograde flow
in the azygos vein.
from the catheter (Fig. 1A). The wire has a more rigid structure, with
a maximum diameter of 20 mm and a length (fully open) of 70 mm
(Fig. 2A). The constrained length of the stent is 10 cm, fixed on a
90-cm introducer. The new Wallstent (Schneider Europe, Bu¨lach,
Switzerland) is a noncoated version of the esophageal Wallstent. Sin-
gle and double Z-stents (William Cook Europe, Bjaeverskor, Den-
mark) were used in the other patients (Fig. 1B). The expandable
metallic Z-stents are constructed of a stainless-steel wire bent in a
zigzag pattern to form a cylinder. This stent is compressed and intro-
duced through a Teflon catheter (length 60–90 cm, diameter 10 Fr)
depending on the caliber of the wire and the diameter of the stent.
When the stent is released from the catheter, it expands to its original
diameter. The fully expanded stent diameter is 20 mm, and the stent
length varies from 20 mm (single), to 50 mm (double) (Fig. 2B), to
70 mm (double plus single). The mean length of vessel occlusion in
the patients who received Wallstents was 6.23 cm, with the stented
segment varying from 7 to 8 cm. The mean length of vessel occlusion
in patients who received Z-stents was 5.13 cm, with a mean stented
segment of 6.1 cm.
In the statistical analysis the percentage of successful results was
determined on the day of the procedure and at 2 weeks. These data
were compared using Fisher’s exact test for a 2 1 2 or a 3 1 2 table
(significance level 5%). Survival times were compared with the log-
rank test.
Results
During a 36-month period, 54 patients with cancer were
referred for a stenting procedure of the SVC. Thirty of
them had a vessel occlusion of 75%–100% and had
developed collateral flow, making them eligible to un-
dergo the procedure. Twenty-four patients were ex-
cluded due to contraindications, mainly chronic
complete obstruction (14 patients). The 30 eligible pa-
tients had had a relapse of SVCS caused by recurrent
malignant disease, and all had previously been treated
with chemotherapy, radiation therapy, or both. Patient
characteristics are shown in Table 1.
Z-stents were placed in 17 patients; 94% (16 of 17)
of the stents were of the double Z-type. One patient
received a double plus single Z-stent (Fig. 3). The new
Wallstents were placed in 13 patients (Figs. 4, 5; Table
2). Most stents were opened to a maximum diameter
of 10–20 mm. In 2 patients the maximum expanded
diameter was less than 10 mm (one Z-stent, one Wall-
stent). The stents were positioned correctly in all pa-
tients. The mean prestent lumen was 9% in the Z-stent
patients, and the mean poststent lumen improved to
59% of the original lumen diameter. The mean prestent
lumen was 8% in the Wallstent patients, and their mean
poststent lumen improved to 66% of the original lumen
diameter. Despite heparin and streptokinase prophy-
laxis, stent occlusion due to acute thrombosis occurred
within 12 hr in 4 of the 17 patients who were given a
Z-stent (24%). The SVC was opened successfully in all
of these 4 patients with a repeated bolus injection of
50,000 U of streptokinase (to a maximum of 150,000
U) through the catheter, with the tip in the thrombus.
After 2 weeks, all 17 Z-stents were open with complete
relief of symptoms.
Among the 13 patients who received Wallstents,
complete relief of symptoms was achieved in 12 (92%)
and no signs of thrombosis were seen. One patient had
acute stent occlusion and died from massive hemop-
tysis during thrombolytic therapy. After 2 weeks, how-
ever, recurrence of the clinical syndrome with complete
Wallstent occlusion was found in 3 patients (23%) (Fig.
6A, B), and the lumen failed to reopen permanently
even after local streptokinase treatment. Partial occlu-
sion with minor clinical symptoms (e.g., headaches,
continuing discomfort in the supine position) was seen
in 6 patients (46%) (Fig. 6C). The patients with partial
occlusion required no further treatment because there
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Fig. 4. A Cavography in left oblique projection. A
catheter from the right femoral vein passes the ste-
nosis in the SVC, which is subtotally obstructed by
tumor compression and thrombosis (arrow). B Cav-
ography in postero-anterior projection 3 months after
stent placement of a Wallstent in the SVC. There is
complete restoration of flow through the SVC. Note
that the structure of the Wallstent is hardly recogniz-
able in the subtraction image.
Fig. 5. A Cavography before stent placement. Subto-
tal obstruction is seen for more than 5 cm in the
SVC by tumor compression (t in arrowhead). B Cav-
ography immediately after Wallstent placement
shows unimpaired flow through the SVC. Collateral
flow is no longer seen.
was no recurrence of the full SVCS. Only 3 patients
(23%) did not develop thrombosis during the follow-
up period. No sign of stent migration was noted in this
series of patients. Because the disease in these patients
was no longer amenable to available treatment, no ad-
ditional antitumor therapy was given. The mean fol-
low-up period until death was 2.5 months (range 0.5–
34 months). No change in clinical status from 2 weeks
until death was recorded in either patient group.
The difference between the percentages of stent oc-
clusion on the day of the procedure for the Z-stents and
the Wallstents was not statistically significant (p 
0.36). However, the difference in the distribution of
occlusion percentages for the two stent types at 2 weeks
was highly significant (p  0.008). Of the 30 patients
treated, no patient is still alive; and there was no sig-
nificant difference in survival between the two study
groups (p  0.82).
Discussion
In this prospective series of 30 patients with recurrent
SVCS after radiotherapy, chemotherapy, or both, the
overall clinical success rate was 69% for the new Wall-
stent and 100% for the Z-stent. In patients who had
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Fig. 6. Three patients with stent thrombosis. A Cavography 3 days
after the stent procedure shows complete obstruction of flow in half
the lumen of the Wallstent (arrow). B Cavography 3 months after the
stent procedure. Complete obstruction of the right anonymous vein
is seen at the proximal end of the Wallstent, which has the configu-
ration of a trumpet (arrow). Note that there is still flow from the left
anonymous vein to the SVC. C Cavography 1 day after the stent
procedure along the left anonymous vein. A partial thrombosis is seen
within the lumen of the Wallstent (arrow).
received the new Wallstent, the complete occlusion rate
at 2 weeks was 23%. Patients with the Z-stent showed
complete occlusion earlier, within 12 hr after the pro-
cedure (24%). The two stent types may thus have about
the same rate of thrombotic occlusion but at different
points in time, with the new Wallstent developing oc-
clusion later than the Z-stent.
The new Wallstent is longer (70 mm) than the
Z-stent, shows less shortening after placement than
the original vascular stent, and has a more compact
wire structure. The more rigid structure of this stent
could prohibit tumor infiltration. The Z-stent has a
more open structure, which allows easy tumor infil-
tration. Clot formation on the stent wire is a major
problem during vascular stent procedures, causing ste-
nosis and occlusion.
Although stent thrombosis is an important issue
associated with arterial stenting, prospective clinical
data are scarce for venous stenting. Thromboses in
venous stents have occasionally been noted in case
reports and retrospective data [7–11]. Stent throm-
bosis of Wallstents has also been mentioned in con-
junction with transjugular intrahepatic portosystemic
shunt procedures [12], although leakage of bile from
the hepatic tract may play a role here. It could be ar-
gued that stent occlusion was the result not of stent
thrombosis but of tumor growth. The following ar-
guments suggest otherwise. First, one would expect
that thrombosis would occur in the stent with the more
open structure, which is the Z-stent. This was not the
case here. Second, during streptokinase treatment a
remarkable improvement of flow through the stent
was noted in all control studies. With the Z-stents this
reopening could be maintained, but with the Wall-
stents occlusion recurred after stopping streptokinase
treatment in the 3 patients who ultimately developed
complete occlusion. Third, it seems unlikely that tu-
mor growth could be responsible for stent occlusion
within only a few days. Although the complete occlu-
sion rates between Z-stents and Wallstents are com-
parable, Z-stents seem to be more easily recanalized
than Wallstents, resulting in better overall patency.
The acute occlusion in Z-stents is probably due to the
damaging force on the vessel wall at the moment of
Z-stent unfolding. Moreover, the Z-stent design in-
cludes several barbs to prevent stent migration.
The reason for clot formation on the new Wallstents
may be related to the relatively small distance between
the wires and the impaired flow in the SVC compared
with that with the Z-stents. It has been demonstrated
that the amount of fibrin–platelet thrombus deposited
is proportional to the total metal surface of the stent
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Table 2. Wallstent versus Z-stent for malignant superior vena caval
obstruction
Z-stenta
(n  17)
Wallstentb
(n  13)
Day of procedure
Recanalization 13 (76%) 12 (92%)
Occlusion 4a (24%) 1 (8%)c
At 2 weeks after procedure
Stent open 12 (71%) 3 (23%)
Stent partially open 5 (29%) 6 (46%)
Stent occluded 0 3 (23%)
a All patients received full-dose heparin therapy beginning 1 day
before the procedure and continuing for at least 3 days after the
procedure. Four patients were successfully treated with selective
streptokinase infusion
b All patients received full-dose heparin therapy beginning 1 day
before the procedure and continuing for at least 3 days after the
procedure. Simultaneously, they were given selective streptokin-
ase injection on the day of procedure up to 1 day after the pro-
cedure
c Patient with acute stent occlusion who died during thrombolytic
therapy
[13]. If stents are expanded to a larger diameter, the
thrombus spreads over a proportionally larger surface,
which reduces the lumen diameter and decreases flow
[14]. The fine metal wire structure of the new Wallstent
appears to allow less tumor invasion, although the
larger total metal surface increases the risk of throm-
bosis. The Z-stent contains less steel material in rela-
tion to the surface area of the vessel. Because the
diameter of the Wallstents placed in the SVC did not
differ significantly from that of the Z-stent, we believe
that the more extensive total metal surface of the new
Wallstent, as compared with that of the Z-stent, is in-
volved in the increased thrombogenicity of the Wall-
stent. Another explanation might be that the Wallstents
initially did not open completely. During the expansion
that follows over time, the stent places stress on the
intimal wall of the vessel, which could damage the ves-
sel wall and cause secondary thrombosis. In 2 patients
of this series the stents did not optimally dilate, and the
reduced flow precipitated local thrombosis. Both pa-
tients showed only partial thrombosis after 2 weeks.
Failure of anticoagulant treatment seems unlikely be-
cause the anticoagulant therapy in our study was care-
fully monitored in all patients. According to our data
there was no reason to assume that the stent occlusions
were due to anticoagulation failures.
Despite the open structure of the Z-stent, which
may allow easy tumor ingrowth and infiltration, it is
preferred for stent treatment of SVCS because of the
smaller number of thrombotic complications. However,
except for clinical follow-up, only short-term cavog-
raphy results are available. It should be noted that a 2-
week follow-up is not sufficient time to assess how
these stents would cope with local tumor ingrowth.
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